ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Dec 03, 2018||ENDRA Life Sciences to Present at the 11th Annual LD Micro Main Event on December 5, 2018|
|Nov 26, 2018||ENDRA Life Sciences to Present at Upcoming Investor Conferences|
|Nov 13, 2018||ENDRA Life Sciences Announces Closing of Public Offering and Exercise of Over-Allotment Option|
|Nov 08, 2018||ENDRA Life Sciences Prices Public Offering of Common Stock|
|Nov 07, 2018||ENDRA Life Sciences Announces Proposed Public Offering of Common Stock|
|Day Range||2.10 - 2.34|
|52 Week Range||1.55 - 5.88|
|Bid/Ask||2.11 / 2.15|
|Bid/Ask Size||200 X 500|
|Market Cap||11.61 million|
|Shares Outstanding||5.43 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|